First approved TIL therapy scaling toward NSCLC and sarcoma, with confirmatory Phase 3 data the pivot from accelerated to full approval

Iovance is a commercial-stage cell therapy company whose approved lead product treats melanoma, and it is seeking to expand into non-small-cell lung cancer and sarcoma, which are not yet approved for treatment by this therapy.

Iovance holds the only approved tumor-infiltrating lymphocyte therapy in solid tumors, generating $99M in quarterly revenue and expanding into NSCLC and sarcoma on single-arm accelerated-approval data. The thesis advances if IOV-LUN-202 secures FDA accelerated approval in NSCLC and TILVANCE-301 converts the melanoma label to full approval, and falters if either single-arm package draws a complete response letter. The central risk is regulatory: both the NSCLC sBLA and the confirmatory melanoma filing rest on uncontrolled data, a path the FDA has scrutinized with increasing skepticism.